Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline Drugs Market Report Overview
Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas that originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include a lump or swelling in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles, and dizziness or loss of balance. Treatment includes surgery, radiotherapy, and chemotherapy.
The Peripheral Nerve Sheath Tumors drugs in development market research report provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Nerve Sheath Tumors and features dormant and discontinued projects.
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Segmentation by Targets
Some of the targets in the Peripheral Nerve Sheath Tumors pipeline are Programmed Cell Death Protein 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, and Mast/Stem Cell Growth Factor Receptor Kit among others. Programmed Cell Death Protein 1 was the largest target in the pipeline.
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Targets
more Peripheral Nerve Sheath Tumors pipeline drugs market target insights, download a free report sample
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the mechanisms of action in the Peripheral Nerve Sheath Tumors pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor among others. Programmed Cell Death Protein 1 Antagonist was the leading MoA in the pipeline.
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Mechanisms of Action
For more MoA insights into the Peripheral Nerve Sheath Tumors pipeline drugs market, download a free report sample
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Peripheral Nerve Sheath Tumors pipeline drugs market are intravenous, oral, intraperitoneal, and intrapleural among others. The majority of the pipeline drugs followed the oral route of administration.
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Peripheral Nerve Sheath Tumors pipeline drugs market, download a free report sample
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Segmentation by Molecule Types
The leading molecule types in the Peripheral Nerve Sheath Tumors pipeline drugs market are small molecule, monoclonal antibody, and oncolytic virus among others. Small molecule was the leading molecule type in the pipeline.
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Peripheral Nerve Sheath Tumors pipeline drugs market, download a free report sample
Peripheral Nerve Sheath Tumors Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Peripheral Nerve Sheath Tumors pipeline drugs market are Bristol-Myers Squibb Co, Calithera Biosciences Inc, Epizyme Inc, and Mirati Therapeutics Inc among others.
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis by Key Companies
To know more about the Peripheral Nerve Sheath Tumors pipeline drugs market companies, download a free report sample
Peripheral Nerve Sheath Tumors Pipeline Drugs Market Report Overview
Key Targets | Programmed Cell Death Protein 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, and Mast/Stem Cell Growth Factor Receptor Kit |
Key Mechanism of Actions | Programmed Cell Death Protein 1 Antagonist, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor |
Key Routes of Administration | Intravenous, Oral, Intraperitoneal, and Intrapleural |
Key Molecule Types | Small Molecule, Monoclonal Antibody, and Oncolytic Virus |
Key Companies | Bristol-Myers Squibb Co, Calithera Biosciences Inc, Epizyme Inc, and Mirati Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
Aldeyra Therapeutics Inc
Apexian Pharmaceuticals Inc
Ascentage Pharma Group International
AstraZeneca Plc
BeiGene Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Eisai Co Ltd
Epizyme Inc
F. Hoffmann-La Roche Ltd
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Merck & Co Inc
Mirati Therapeutics Inc
Moleculin Biotech Inc
Novartis AG
Oncomatryx Biopharma SL
Open Therapeutics LLC
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
Tango Therapeutics Inc
Vyriad Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Peripheral Nerve Sheath Tumors pipeline drugs market?
Some of the key targets of the Peripheral Nerve Sheath Tumors pipeline drugs market are Programmed Cell Death Protein 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, and Mast/Stem Cell Growth Factor Receptor Kit.
-
What are the key mechanisms of action in the Peripheral Nerve Sheath Tumors pipeline drugs market?
Some of the key mechanisms of action in the Peripheral Nerve Sheath Tumors pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor.
-
What are the key routes of administration in the Peripheral Nerve Sheath Tumors pipeline drugs market?
The key routes of administration in the Peripheral Nerve Sheath Tumors pipeline drugs market are small molecule, monoclonal antibody, and oncolytic virus.
-
What are the key molecule types in the Peripheral Nerve Sheath Tumors pipeline drugs market?
The molecule types in the Peripheral Nerve Sheath Tumors pipeline drugs market are small molecule, monoclonal antibody, and oncolytic virus.
-
Which are the key companies in the Peripheral Nerve Sheath Tumors pipeline drugs market?
Some of the key companies in the Peripheral Nerve Sheath Tumors pipeline drugs market are Bristol-Myers Squibb Co, Calithera Biosciences Inc, Epizyme Inc, and Mirati Therapeutics Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.